Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Recruiting

Phase 2

Phase 3

ELA026Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Sponsor:

Electra Therapeutics Inc.

Code:

NCT05416307

Conditions

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Eligibility Criteria

Sex: All

Age: 6+

Healthy Volunteers: Not accepted

Interventions

ELA026

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-13. This information was provided to ClinicalTrials.gov by Electra Therapeutics Inc. on 2026-05-01.